Elsevier

The Lancet

Volume 321, Issue 8325, 19 March 1983, Pages 612-615
The Lancet

MISMATCHED FAMILY DONORS FOR BONE-MARROW TRANSPLANTATION AS TREATMENT FOR ACUTE LEUKAEMIA

https://doi.org/10.1016/S0140-6736(83)91793-2Get rights and content

Abstract

35 patients were treated for acute myeloid leukaemia or acute lymphoblastic leukaemia with allogeneic bone-marrow grafts from a parent, child, or sibling who was mismatched at the major histocompatibility complex (MHC). 11 of these patients are alive at least 6 months after grafting, 5 of them after more than 2 years. Of the 15 patients aged under 20 at the time of the graft, 8 are alive and well 6 months to 3 years later. Cyclosporin A was given to all patients after grafting. 1 patient died of acute graft-versus-host disease and in 2 other cases this was a major factor in their death. Graft failure caused the death of 2 patients. 4 patients died of recurrent leukaemia. A fatal complication in 12 patients was pulmonary oedema, often associated with convulsions, intravascular haemolysis, and renal failure. Some of these patients had viral or bacterial infections, but in the majority the syndrome was not associated with demonstrable infection. This syndrome, in which the essential lesion appears to be vascular, was much more common in recipients of mismatched than matched grafts. 3 others died from lung disease in which infection was a factor.

References (16)

There are more references available in the full text version of this article.

Cited by (214)

  • Haploidentical transplants with a G-CSF/ATG-based protocol: Experience from China

    2023, Blood Reviews
    Citation Excerpt :

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curative option for treating hematologic malignant and non-malignant conditions. Initially, allo-HSCT could only be performed between human leukocyte antigen (HLA)-matched donors and recipients because a formidable HLA barrier led to high incidences of graft failure (GF) and graft versus host disease (GvHD) [1,2]. In recent decades, haploidentical donor stem cell transplantation (haplo-SCT), especially non T cell depletion in vitro strategies, including the granulocyte colony-stimulating factor (G-CSF)/antithymocyte globulin (ATG)-based Beijing protocol and the posttransplantation cyclophosphamide (PT-Cy)-based Baltimore protocol, have made great advances.

  • Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective

    2022, Transplantation and Cellular Therapy
    Citation Excerpt :

    As larger numbers of patients are treated with CD19 CAR T for B-ALL, leveraging cellular therapy registries may provide insight and predictive modeling that could inform decisions on whether to proceed to consolidative allo-HCT after CD19 CAR T cell therapy. The pioneering work in both allo-HCT and auto-HCT, although initially met with skepticism and frustration, eventually demonstrated the curative potential of these modalities in advanced, otherwise fatal hematologic malignancies [21,69-73]. By circumventing the dose-limiting toxicity of myeloablation, these therapies greatly increased the therapeutic windows for cytotoxic chemotherapy regimens and, in the case of allo-HCT, unlocked the immunotherapeutic benefit of the donor immune system.

View all citing articles on Scopus
View full text